Affordable Access

deepdyve-link
Publisher Website

Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19

Authors
  • Dugas, Martin1
  • Grote-Westrick, Tanja2
  • Merle, Uta3
  • Fontenay, Michaela4, 5
  • Kremer, Andreas E.6
  • Hanses, Frank7, 8
  • Vollenberg, Richard9
  • Lorentzen, Eva2
  • Tiwari-Heckler, Shilpa3
  • Duchemin, Jérôme4
  • Ellouze, Syrine4
  • Vetter, Marcel6
  • Fürst, Julia6
  • Schuster, Philipp10
  • Brix, Tobias1
  • Denkinger, Claudia M.11, 12
  • Müller-Tidow, Carsten13
  • Schmidt, Hartmut9
  • Tepasse, Phil-Robin9
  • Kühn, Joachim2
  • 1 Institute of Medical Informatics, University of Münster, Germany
  • 2 Institute of Virology, Department of Clinical Virology, University Hospital Münster, Germany
  • 3 Medizinische Klinik, Abteilung Innere Medizin IV, University Hospital Heidelberg, Germany
  • 4 Assistance Publique-Hôpitaux de Paris, AP-HP. Centre-Université de Paris, Hôpital Cochin, Service d'hématologie biologique, Paris, France
  • 5 Université de Paris, Institut Cochin, CNRS UMR8104, INSERM, Paris U1016, France
  • 6 Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
  • 7 Emergency Department, University Hospital Regensburg, Germany
  • 8 Department for Infectious Diseases and Infection Control, University Hospital Regensburg, Germany
  • 9 Medizinische Klinik B (Gastroenterologie, Hepatologie, Endokrinologie, Klinische Infektiologie), University Hospital Münster, Germany
  • 10 Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
  • 11 Division of Tropical Medicine, Center of Infectious Diseases, University Hospital Heidelberg, Germany
  • 12 German Centre for Infection Research (DZIF), partner site Heidelberg University Hospital, Heidelberg, Germany
  • 13 Medizinische Klinik, Abteilung Innere Medizin V, University Hospital Heidelberg, Germany
Type
Published Article
Journal
Journal of Clinical Virology
Publisher
The Author(s). Published by Elsevier B.V.
Publication Date
Apr 24, 2021
Volume
139
Pages
104847–104847
Identifiers
DOI: 10.1016/j.jcv.2021.104847
PMID: 33965698
PMCID: PMC8065244
Source
PubMed Central
Keywords
Disciplines
  • Original Article
License
Unknown

Abstract

Background The vast majority of COVID-19 patients experience a mild disease. However, a minority suffers from critical disease with substantial morbidity and mortality. Objectives To identify individuals at risk of critical COVID-19, the relevance of a seroreactivity against seasonal human coronaviruses was analyzed. Methods We conducted a multi-center non-interventional study comprising 296 patients with confirmed SARS-CoV-2 infections from four tertiary care referral centers in Germany and France. The ICU group comprised more males, whereas the outpatient group contained a higher percentage of females. For each patient, the serum or plasma sample obtained closest after symptom onset was examined by immunoblot regarding IgG antibodies against the nucleocapsid protein (NP) of HCoV 229E, NL63, OC43 and HKU1. Results Median age was 60 years (range 18-96). Patients with critical disease ( n =106) had significantly lower levels of anti-HCoV OC43 nucleocapsid protein (NP)-specific antibodies compared to other COVID-19 inpatients ( p =0.007). In multivariate analysis (adjusted for age, sex and BMI), OC43 negative inpatients had an increased risk of critical disease (adjusted odds ratio (AOR) 2.68 [95% CI 1.09 - 7.05]), higher than the risk by increased age or BMI, and lower than the risk by male sex. A risk stratification based on sex and OC43 serostatus was derived from this analysis. Conclusions Our results suggest that prior infections with seasonal human coronaviruses can protect against a severe course of COVID-19. Therefore, anti-OC43 antibodies should be measured for COVID-19 inpatients and considered as part of the risk assessment for each patient. Hence, we expect individuals tested negative for anti-OC43 antibodies to particularly benefit from vaccination against SARS-CoV-2, especially with other risk factors prevailing.

Report this publication

Statistics

Seen <100 times